Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interleukin immunotherapy of progression].

A Mandressi1

  • 1Istituto di Urologia, Università degli Studi di Milano.

Archivio Italiano Di Urologia, Nefrologia, Andrologia : Organo Ufficiale Dell'Associazione Per La Ricerca in Urologia = Urological, Nephrological, and Andrological Sciences
|June 1, 1991
PubMed
Summary

Interleukin-2 (IL-2) therapy shows promise for metastatic renal cancer, inducing tumor regression. Careful administration and monitoring are crucial due to dose-related toxicities, which are reversible.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does site of specimen extraction affect incisional hernia rate after robot assisted laparoscopic radical prostatectomy?

International journal of surgery (London, England)·2017
Same author

Thulium laser enucleation (ThuLEP) versus transurethral resection of the prostate in saline (TURis): A randomized prospective trial to compare intra and early postoperative outcomes.

Actas urologicas espanolas·2017
Same author

Proposal for a "European Scoring System for Laparoscopic Operations in Urology".

European urology·2001
Same author

[Urologic laparoscopy in day hospital].

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·1998
Same author

Long-term results of intrarenal surgery for branched calculi: is such surgery still valid?

British journal of urology·1998
Same author

Transurethral electrovaporization of the prostate vs. transurethral resection. Results of a multicentric, randomized clinical study on 150 patients.

European urology·1998

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Interleukin-2 (IL-2) is a lymphokine with significant in vivo immunomodulatory effects.
  • IL-2 administration can enhance cellular immune responses, promote lymphocyte proliferation, and stimulate cytokine production.
  • Recombinant IL-2 availability allows for investigation into its therapeutic use for metastatic renal cancer, alone or with lymphokine-activated killer (LAK) cells.

Purpose of the Study:

  • To evaluate the therapeutic potential of Interleukin-2 (IL-2) in treating metastatic renal cancer.
  • To explore optimal administration strategies for IL-2 therapy, including dosage, infusion methods, and the role of LAK cells.
  • To characterize the toxicity profile of IL-2 therapy and its management.

Main Methods:

  • Review of studies investigating IL-2 administration for metastatic renal cancer.
  • Analysis of different administration routes (intravenous, subcutaneous) and schedules (bolus vs. continuous infusion).
  • Assessment of the efficacy and toxicity of IL-2, with or without LAK cells.

Main Results:

  • IL-2 administration has demonstrated the ability to induce durable tumor regression in a notable percentage of patients with metastatic renal cancer.
  • Therapy toxicity is dose-dependent, manifesting as vascular capillary leak syndrome, lymphocytic infiltration, and cytokine release.
  • Observed side effects are reversible upon discontinuation of IL-2 therapy.

Conclusions:

  • IL-2 therapy offers a viable option for inducing tumor regression in metastatic renal cancer.
  • Careful consideration of administration protocols and patient monitoring is essential to manage IL-2-related toxicities.
  • The reversible nature of side effects and potential for rapid patient recovery underscore the manageability of IL-2 therapy.

Related Experiment Videos